A detailed allergy history is central to all history taking and medical records. It is also mandatory before anesthesia or contrast exposure. Owing to medical legal consequences and the availability of a wider drug repertoire, drug rechallenges or desensitization are now less frequently performed. There are few systematic data on the validity of drug reaction history after allogeneic stem cell transplantation (HSCT). 1 The central, computerized patient registry of the Hong Kong Hospital Authority requires mandatory entry of all drug allergy history and it automatically documents all subsequent drug prescriptions and reactions. Among 763 consecutive adult HSCT recipients, a known history of pre-HSCT allergic drug reaction was registered in 175 cases (22.9%). The most commonly implicated drugs were penicillin group antibiotics (including cephalosporin and imipenem, n ¼ 64), allopurinol (n ¼ 30), cotrimoxazole (n ¼ 21), vancomycin (n ¼ 14), intravenous contrast (n ¼ 9) and cytosine arabinoside (n ¼ 10). Multiple drug allergies were documented in 55 cases (32% of allergic patients), and skin rash was the most common manifestation (95.4% of cases). Skin tests to document sensitivity were not performed. At a median follow-up of 37 months, 16 patients had documented re-exposure to the same mediation (9.1%, median 8 months, range 2-24 months after HSCT). The overriding clinical decisions for exposure were based on microbial sensitivity, severity of patient condition and intolerance or inefficiency of alternative agents (for example pentamidine inhalation). 2 The re-challenged drugs included vancomycin (n ¼ 4), cotrimoxazole (n ¼ 6), allopurinol (n ¼ 3), tienam (n ¼ 2) and amphotericin (n ¼ 1). No adverse reaction was documented in any case with no desensitization, 3 even in relapsed patients with theoretical loss of donor chimerism.
It is uncertain whether allergic tendencies remain stable throughout life, or whether they can be modified by chemotherapy and immunosuppression. Many drug reactions are immune-mediated, and repeat challenges may lead to more severe amnenestic reactions. In HSCT recipients, the newly engrafted immune system is completely donor replaced. Full revaccination is needed for HSCT recipients. There are many reports of secondary resolution of autoimmune diseases with HSCT, and HSCT is occasionally used as a primary treatment for refractory autoimmune diseases. Adoptive transfer of autoimmune diseases and antiviral immunity from donor to recipient is also well recognized. Therefore our data, which showed that pre-HSCT drug allergies are no longer manifest after engraftment, confirmed something that is hardly surprising. The concurrent immunosuppression and high-dose conditioning also suppresses any residual old (and new) allergic reactions. 4 Conversely, the onset of skin GVHD may be temporally related to drug exposure, and its clinical and histological differentiation from 'new' drug allergy may be difficult and occasionally impossible. 5, 6 Hence, no medication can be considered 'safe' to the new and developing immune system after HSCT. Polypharmacy and over-thecounter prescriptions must be discouraged in this patient population. On the other hand, our retrospective survey data showed that the pre-HSCT drug allergy history should not limit the choice of medication, especially if the immediate clinical benefit is likely to outweigh the theoretical risk. 7 It would be interesting if our retrospective observations could be confirmed by prospective HSCT allergy studies integrating skin tests pre-and post-HSCT for allergic patients.
